Catalent acquiring Boston's Juniper Pharmaceuticals for $128M
Drug contract manufacturer Catalent has agreed to acquire Boston-based Juniper Pharmaceuticals for $128 million, the companies announced.
Under the deal, New Jersey-based Catalent (NYSE: CTLT) will acquire all of Juniper’s (Nasdaq: JNP) shares for $11.50 per share. That values Juniper at a 60 percent premium to its share price on Jan. 30, the last trading day before the company announced that it was exploring a potential sale.
Ju niper provides drug development and manufacturing services to other…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Max Stendahl Source Type: news